Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 138 of 5804
-
Simple blood test could spare thousands from unneeded colonoscopies
Diagnosis Not yet recruitingColorectal Cancer (CRC), or bowel cancer, is a serious disease that affects many people globally. The earlier CRC is diagnosed, the better the patient outcomes. The problem with the current diagnostic methods is that they lead to many unnecessary endoscopies (colonoscopies). In …
Sponsor: Nordsjaellands Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 08:12 UTC
-
New ALS drug trial aims to slow disease progression
Disease control Not yet recruitingThe objectives of this study are to examine the effects of tazbentetol on clinical measures of ALS, patient reported outcomes (PROs), long-term safety and tolerability.
Phase: PHASE2, PHASE3 • Sponsor: Spinogenix • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug combo aims to shrink tumors in advanced breast cancer
Disease control Recruiting nowThe study is being conducted to evaluate the clinical efficacy of HLX22 in combination with HLX87 as first-line treatment in patients with HER2-positive recurrent or metastatic breast cancer
Phase: PHASE2, PHASE3 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 11:04 UTC
-
Antibiotic shield: doxycycline may stop STIs in young women
Prevention Recruiting nowThe goal of this open-label, randomized trial is to assess the efficacy of doxycycline prophylaxis in reducing incidences of bacterial sexually transmitted infections (STIs) among adolescent and young adult females while also evaluating acceptability and antimicrobial resistance …
Phase: PHASE4 • Sponsor: Westat • Aim: Prevention
Last updated Jun 27, 2026 12:32 UTC
-
New targeted drug combo aims to curb relapse in kids with rare immune disorder
Disease control Recruiting nowLangerhans cell histiocytosis (LCH) is the most common histiocytic disorder in children, caused by excessive proliferation and accumulation of Langerhans cells (a type of immune cell) in various body tissues. The annual incidence is about 2.6-8.9 cases per million children.Clinic…
Phase: NA • Sponsor: West China Second University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New weekly shot aims to treat sleep apnea and obesity together
Disease control Recruiting nowThe purpose of the studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight. YDAO is a master protocol designed to support two independent studies: YSA1 and YSA2. Study YSA1 will inclu…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Could white blood cells boost cord transplants for tough leukemia?
Disease control Not yet recruitingAllogeneic stem cell transplantation is the only potentially curative therapy for patients with high-risk Acute Myeloid Leukaemia, but relapse is common and remains the leading cause of death. Patients with certain mutations and those transplanted without first clearing their dis…
Phase: PHASE1, PHASE2 • Sponsor: University of Manchester • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
CAR t cells aim to lock in remission for leukemia patients
Disease control Recruiting nowThe researchers are doing this study to find out whether obecabtagene autoleucel (obe-cel) is an effective treatment for people with B-cell acute lymphoblastic leukemia (ALL) that is in complete remission (CR, meaning all signs of cancer are gone) with no measurable residual dise…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Immunotherapy combo shows promise in battling esophageal cancer before surgery
Disease control Not yet recruitingThis study is a randomized, controlled, open-label, multicenter Phase III clinical trial, designed to evaluate the efficacy and safety of neoadjuvant toripalimab in combination with nab-paclitaxel and platinum versus neoadjuvant docetaxel in combination with cisplatin and 5-fluor…
Phase: PHASE3 • Sponsor: Tang-Du Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Radiation vs. scalpel: landmark trial seeks best treatment for small liver tumors
Disease control Not yet recruitingHepatocellular carcinoma (HCC) is one of the leading causes of cancer-related incidence and mortality in China and represents a major public health challenge. Surgical resection is the most commonly used curative treatment for HCC and can provide favorable long-term outcomes. How…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
AI reads chest X-Rays to catch kawasaki disease earlier in kids
Diagnosis Not yet recruitingThe goal of this observational study is to develop an AI-based early warning system for Kawasaki Disease (KD) using chest X-rays (CXR) in children diagnosed with Kawasaki Disease. The main question\[s\] it aims to answer are: 1. Can AI modeling of CXR features help identify high…
Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Diagnosis
Last updated Jun 27, 2026 09:04 UTC
-
Engineered immune cells take on tough lupus cases
Disease control Recruiting nowThis is an investigator-initiated trial aimed at assessing the safety and efficacy of PTOC1 cells Injection in the treatment of refractory systemic lupus erythematosus.
Phase: PHASE1 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New combo aims to beat rectal cancer without surgery
Disease control Recruiting nowIn pMMR/MSS locally advanced rectal cancer, can the innovative "chemo-immunotherapy induction + LCRT + chemo-immunotherapy consolidation" approach significantly improve the complete response rate and create opportunities for organ preservation?
Phase: PHASE2 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New combo therapy aims to boost survival in head and neck cancer patients
Disease control Not yet recruitingThis is a prospective, randomized, controlled, multicenter, non-inferiority clinical study designed to evaluate the efficacy and safety of camrelizumab combined with EGFR monoclonal antibody or chemotherapy as perioperative treatment of locally advanced head and neck squamous cel…
Phase: PHASE3 • Sponsor: Yue He, MD • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Engineered immune cells take on lupus and other autoimmune diseases
Disease control Not yet recruitingThe purpose of this study is to assess the safety and efficacy of CD19 UCAR-T cell therapy in Subjects with autoimmune diseases.
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Eye implant could restore sight after retinal vein blockage
Disease control Recruiting nowThis is a multicenter, randomized, double-masked, parallel-group, active-controlled Phase 3 clinical trial designed to evaluate the efficacy and safety of SMO1 (Dexamethasone 700μg intravitreal implant) compared with the reference drug (Dexamethasone 700μg intravitreal implant) i…
Phase: PHASE3 • Sponsor: SANGMYUNG innovation • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Could KarXT be the key to treating teen schizophrenia?
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of KarXT for treatment of Schizophrenia in adolescents.
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New immune cell therapy takes on childhood cancers that Won't quit
Disease control Recruiting nowThis is a phase I dose-escalation study to determine the safety and feasibility of autologous CAR-TA T cells (B7-H3 CAR+ T cells administered with DNR-PRAME Tumor Antigen-specific T cells) following lymphodepleting chemotherapy in participants with relapsed/refractory rhabdomyosa…
Phase: PHASE1 • Sponsor: Children's National Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug combo aims to shrink oral cancers before surgery
Disease control Recruiting nowTo investigate the neoadjuvant chemoimmunotherapy regimen of Ivonescimab combined with chemotherapy (Paclitaxel plus Cisplatin/Carboplatin) for the treatment of locally advanced resectable oral squamous cell carcinoma and oropharyngeal squamous cell carcinoma.
Sponsor: Zhujiang Hospital • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New hope for Crohn's: duvakitug enters final phase 3 trial
Disease control Recruiting nowThis is a multicenter, randomized, double-blind, placebo-controlled, maintenance, Phase 3 study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease (CD). Study details include: The study duration may be up to 286 we…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC